- Press Contact
- Global Marketing Manager
In an Irish study the researchers investigated the use of TIGR® Matrix long term resorbable mesh in 56 patients undergoing immediate breast reconstructions after mastectomy. The authors concluded that TIGR® Matrix was an effective adjunct for use in breast reconstruction, providing excellent cosmetic outcomes with minimal rates of complications.
A new clinical study evaluating the role of TIGR® Matrix in immediate implant-based breast reconstruction has been published ahead of print by the journal Breast Cancer Management.
Novus Scientific main sponsor at Rome Breast Surgery Symposium 2016
2nd day of the EHS meeting in Rotterdam in the Netherlands.
Today, Thursday May 26 starts the Akademikliniken’s 12th International aesthetic medicine meeting in Stockholm. TIGR® Matrix is of course here! http://www.beautythroughscience.com/
Novus Scientific is showcasing TIGR® Matrix at Paris Breast Rendez- vous 2016 together with the French distributor Aspide Medical. Read more about Novus Scientific and TIGR® Matrix at www.tigrmatrix.com Read more about Aspide Medical at : http://www.aspide.com
TIGR® Matrix at the International Breast Symposium Düsseldorf (IBSD)22-23rd of April 2016.
Novus Scientific (Uppsala, Sweden) is pleased to announce the start of the randomized controlled multicenter study PREVMESH. The study aims at assessing whether a long-term resorbable mesh (TIGR®Matrix) placed onlay after open abdominal surgery decreases the rate of incisional hernias and wound dehiscence.
Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable implants, that is aimed to help the body to heal it self.
Global HQ, R&D and manufacturing is located in Uppsala, Sweden.